What Does the FDA Label Say About Ozempic and Gastroparesis?
From General Health to Specific Safety Concerns
If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis. Decades of pharmacovigilance have established that delayed gastric emptying is a recognized class effect of GLP-1 receptor agonists, and the FDA label now reflects this risk. This page summarizes the label evidence and what it means for patient monitoring.
Understanding Ozempic and Its Gastrointestinal Effects
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes and, in some formulations, for weight management. Its pharmacological action involves slowing gastric emptying, which can lead to a range of gastrointestinal adverse effects. Among the most serious of these is gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, abdominal pain, and early satiety. Clinical presentation and diagnosis of gastroparesis typically involve a history of persistent nausea, vomiting, postprandial fullness, and abdominal discomfort. Diagnosis is confirmed through gastric emptying scintigraphy or other motility studies. In the context of Ozempic use, the drug's known effect on gastric motility raises concern that it may induce or exacerbate gastroparesis. The FDA Adverse Event Reporting System (FAERS) database lists "impaired gastric emptying" as a frequently reported adverse event associated with Ozempic, with 2,693 reports (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). This signal is supported by the drug's prescribing information, which documents gastrointestinal adverse reactions occurring more frequently among patients receiving Ozempic than placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to these reactions was also higher in the Ozempic groups: 3.1% for 0.5 mg and 3.8% for 1 mg, compared to 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% of patients on 1 mg and 34.0% of those on 2 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Mechanistic Link and Clinical Evidence
The mechanistic pathway linking Ozempic to gastroparesis is rooted in its GLP-1 receptor agonist activity. GLP-1 receptors are expressed in the gastrointestinal tract and central nervous system, and their activation slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone. While this effect is intended to improve glycemic control by reducing postprandial glucose excursions, it can become pathological in susceptible individuals, leading to clinically significant delayed gastric emptying. The prescribing information notes that the majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting that the gastrointestinal effects are dose-dependent and may be more pronounced during initial treatment or dose increases. However, the FAERS data indicate that impaired gastric emptying is a persistent concern, with thousands of reports, many of which may represent cases of gastroparesis.
Risk Considerations for Patients and Attorneys
Risk considerations for patients and attorneys center on the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information lists gastrointestinal adverse reactions such as dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the term "gastroparesis" is not explicitly mentioned in these tables, and the label does not provide specific warnings about the risk of developing this condition. This omission may be relevant for patients who experience severe or persistent gastrointestinal symptoms that are not adequately addressed by dose adjustment or discontinuation. For attorneys representing affected patients, key considerations include the timeline between exposure and documented harm. The FAERS data show that impaired gastric emptying is among the most frequently reported adverse events, suggesting that many patients develop symptoms during treatment. The prescribing information indicates that gastrointestinal reactions often occur during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but the duration of exposure before onset of gastroparesis can vary. Patients who develop gastroparesis after starting Ozempic may have a claim if they were not adequately warned of this risk and if the drug caused or contributed to their condition.
Summary of Evidence and Legal Implications
In summary, the evidence from clinical trials and postmarketing surveillance indicates that Ozempic is associated with a significant risk of gastrointestinal adverse effects, including impaired gastric emptying consistent with gastroparesis. The prescribing information documents higher rates of gastrointestinal reactions in Ozempic users compared to placebo, and FAERS data show thousands of reports of impaired gastric emptying. The mechanistic link through GLP-1 receptor-mediated slowing of gastric emptying is well-established. However, the label does not explicitly warn of gastroparesis, which may be a critical gap for patients and their legal representatives. Attorneys evaluating potential cases should consider the timing of symptom onset relative to Ozempic initiation, the presence of other risk factors for gastroparesis, and whether the patient received adequate information about this potential adverse effect.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Ozempic and how does it relate to gastroparesis?
Ozempic (semaglutide) is a GLP-1 receptor agonist used for type 2 diabetes and weight management. It slows gastric emptying, which can lead to gastroparesis, a condition of delayed gastric emptying causing nausea, vomiting, and abdominal pain. The FDA Adverse Event Reporting System has thousands of reports of impaired gastric emptying associated with Ozempic (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC).
What evidence supports the link between Ozempic and gastroparesis?
Clinical trials show higher rates of gastrointestinal adverse reactions in Ozempic users compared to placebo (e.g., 32.7% for 0.5 mg vs. 15.3% for placebo) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The drug's mechanism involves GLP-1 receptor activation that slows gastric emptying, and FAERS data list impaired gastric emptying as a frequent adverse event.
Does the Ozempic label warn about gastroparesis?
The prescribing information does not explicitly mention gastroparesis. It lists gastrointestinal reactions like dyspepsia and gastritis but does not provide specific warnings about gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission may be relevant for legal claims.
What should California patients do if they developed gastroparesis after taking Ozempic?
Patients should seek medical evaluation for gastroparesis and consult an attorney experienced in pharmaceutical litigation. Key factors include timing of symptom onset relative to Ozempic use and whether adequate warnings were provided. An independent eligibility review may be available.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.